On Tuesday, Karyopharm Therapeutics Inc (NASDAQ: KPTI) was -9.36% drop from the session before settling in for the closing price of $0.93. A 52-week range for KPTI has been $0.62 – $1.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 52.21%. When this article was written, the company’s average yearly earnings per share was at 40.73%. With a float of $114.06 million, this company’s outstanding shares have now reached $114.92 million.
Let’s determine the extent of company efficiency that accounts for 325 employees. In terms of profitability, gross margin is 95.86%, operating margin of -89.89%, and the pretax margin is -61.53%.
Karyopharm Therapeutics Inc (KPTI) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Karyopharm Therapeutics Inc stocks. The insider ownership of Karyopharm Therapeutics Inc is 8.52%, while institutional ownership is 53.93%. The most recent insider transaction that took place on Oct 04 ’24, was worth 3,172. In this transaction President and CEO of this company sold 3,607 shares at a rate of $0.88, taking the stock ownership to the 1,135,607 shares. Before that another transaction happened on Sep 04 ’24, when Company’s SVP, General Counsel&Secretary sold 3,971 for $0.72, making the entire transaction worth $2,866. This insider now owns 273,881 shares in total.
Karyopharm Therapeutics Inc (KPTI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 40.73% per share during the next fiscal year.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
You can see what Karyopharm Therapeutics Inc (KPTI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Looking closely at Karyopharm Therapeutics Inc (NASDAQ: KPTI), its last 5-days average volume was 2.34 million, which is a jump from its year-to-date volume of 1.27 million. As of the previous 9 days, the stock’s Stochastic %D was 25.57%. Additionally, its Average True Range was 0.07.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 34.52%, which indicates a significant increase from 10.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 103.23% in the past 14 days, which was higher than the 79.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8052, while its 200-day Moving Average is $1.0248. However, in the short run, Karyopharm Therapeutics Inc’s stock first resistance to watch stands at $0.9035. Second resistance stands at $0.9613. The third major resistance level sits at $0.9902. If the price goes on to break the first support level at $0.8168, it is likely to go to the next support level at $0.7879. Should the price break the second support level, the third support level stands at $0.7301.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
There are 124,684K outstanding shares of the company, which has a market capitalization of 105.45 million. As of now, sales total 146,030 K while income totals -143,100 K. Its latest quarter income was 42,790 K while its last quarter net income were 23,790 K.
